TriangleNaxitamab (NCT05489887)
Naxitamab trial for Neuroblastoma (NCT05489887). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients over twelve months through age 21 with newly diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Stage, age, and biology determine eligibility; limited prior treatment is allowed.
The idea: naxitamab targets GD2 on cancer cells to recruit immune attack. It is added with GM-CSF to five induction chemotherapy cycles. Stem cells are collected after cycle two, and surgery is planned after cycle four or five. Researchers compare responses with historical controls and track survival and toxicity.
This phase 2 study plans 93 patients. Jaqueline Kraveka chairs it; twenty US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.